SMS Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
SMS Pharmaceuticals's earnings have been declining at an average annual rate of -13.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 5.5% per year. SMS Pharmaceuticals's return on equity is 7.5%, and it has net margins of 5.9%.
Key information
-13.8%
Earnings growth rate
-13.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 5.5% |
| Return on equity | 7.5% |
| Net Margin | 5.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How SMS Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,129 | 361 | 615 | 0 |
| 30 Sep 23 | 6,002 | 288 | 598 | 0 |
| 30 Jun 23 | 5,930 | 150 | 571 | 0 |
| 31 Mar 23 | 5,221 | -71 | 560 | 0 |
| 31 Dec 22 | 4,335 | -42 | 535 | 0 |
| 30 Sep 22 | 4,060 | 9 | 532 | 0 |
| 30 Jun 22 | 4,211 | 259 | 517 | 0 |
| 31 Mar 22 | 5,199 | 622 | 515 | 0 |
| 31 Dec 21 | 6,348 | 789 | 499 | 0 |
| 30 Sep 21 | 6,612 | 911 | 475 | 0 |
| 30 Jun 21 | 6,172 | 791 | 442 | 0 |
| 31 Mar 21 | 5,632 | 625 | 415 | 0 |
| 31 Dec 20 | 4,911 | 458 | 405 | 0 |
| 30 Sep 20 | 4,226 | 319 | 398 | 0 |
| 30 Jun 20 | 4,130 | 308 | 386 | 0 |
| 31 Mar 20 | 4,143 | 316 | 410 | 0 |
| 31 Dec 19 | 4,206 | 386 | 398 | 0 |
| 30 Sep 19 | 4,412 | 405 | 389 | 0 |
| 30 Jun 19 | 4,606 | 406 | 366 | 0 |
| 31 Mar 19 | 4,667 | 400 | 372 | 0 |
| 31 Mar 18 | 4,639 | 317 | 343 | 0 |
| 31 Mar 17 | 4,388 | 285 | 288 | 0 |
| 31 Mar 16 | 6,032 | 409 | 406 | 0 |
| 31 Dec 15 | 5,902 | 391 | 579 | 0 |
| 30 Sep 15 | 5,828 | 396 | 566 | 0 |
| 30 Jun 15 | 5,651 | 343 | 330 | 0 |
| 31 Mar 15 | 5,793 | 352 | 533 | 0 |
| 31 Dec 14 | 5,730 | 358 | 504 | 0 |
| 30 Sep 14 | 5,624 | 327 | 493 | 0 |
| 30 Jun 14 | 5,567 | 326 | 282 | 0 |
| 31 Mar 14 | 5,180 | 204 | 455 | 0 |
| 31 Dec 13 | 3,976 | 686 | 372 | 0 |
| 30 Sep 13 | 3,396 | 430 | 350 | 0 |
| 30 Jun 13 | 2,771 | -792 | 187 | 0 |
Quality Earnings: 532815 has high quality earnings.
Growing Profit Margin: 532815 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532815's earnings have declined by 13.8% per year over the past 5 years.
Accelerating Growth: 532815 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 532815 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 532815's Return on Equity (7.5%) is considered low.